MK3475-641
09 Dec 2020
KEYNOTE 641
NCT03834493
Phase III, randomised, double-blind trial of pembrolizumab (MK-3475) plus enzalutamde vs placebo plus enzalutamide in participants with mCRPC
Merck Sharp & Dohme Corp.
Cancer Type | Prostate |
---|---|
Trial Type | Treatment |
Phase | Phase III |
Age Range | 18 years and older |
Sex | Male |
Tumour Stream | Prostate |
Cancer Stage | Metastatic or Widespread |
Anticipated Start Date | 2019-07-28 |
Anticipated End Date | 2024-12-30 |
Hospital | Royal Adelaide Hospital |
---|---|
Clinical Trial Coordinator | Anne Milton |
anne.milton@sa.gov.au | |
Phone | 08 7074 2342 |
Principal Investigator | Professor Hsiang Tan |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs